Last reviewed · How we verify
Osteolytic Lesions of Multiple Myeloma
Approved treatments
- pamidronate · US Department of Veterans Affairs
- Aredia
- Zometa · Novartis
Zometa works by inhibiting the enzyme farnesyl pyrophosphate synthase, which is involved in the mevalonate pathway and ultimately leads to the inhibition of osteoclast activity. - Zometa · University of Arkansas
- Zoledronate · Children's Hospital Medical Center, Cincinnati
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Osteolytic Lesions of Multiple Myeloma patent landscape — cliff calendar, originator estates, attackable patents
- Osteolytic Lesions of Multiple Myeloma treatment landscape brief
- Osteolytic Lesions of Multiple Myeloma treatment updates RSS
Frequently asked questions about Osteolytic Lesions of Multiple Myeloma
What drugs treat Osteolytic Lesions of Multiple Myeloma?
Tracked treatments include pamidronate, Aredia, Zometa, Zoledronate.
What is the treatment for Osteolytic Lesions of Multiple Myeloma?
Standard treatment for Osteolytic Lesions of Multiple Myeloma includes pamidronate, Aredia, Zometa, Zoledronate. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Osteolytic Lesions of Multiple Myeloma patent cliff · Osteolytic Lesions of Multiple Myeloma CI report
- Treatment: pamidronate · US Department of Veterans Affairs
- Treatment: Aredia
- Treatment: Zometa · Novartis
- Treatment: Zometa · University of Arkansas
- Treatment: Zoledronate · Children's Hospital Medical Center, Cincinnati
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing